To include your compound in the COVID-19 Resource Center, submit it here.

Merck's bezlotoxumab meets in two Phase III trials

Merck & Co. Inc. (NYSE:MRK) said bezlotoxumab ( MDX-1388) met the primary endpoint in two Phase III trials to treat Clostridium difficile infection

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE